30 SKIN CARE Inflammatory Markers 125 100 75 50 ** 25 0 Control 0.05% Moringa Seed Extract Figure 3: The moringa seed extract soothes inflammation and provides skin protection and recovery
the synthesis of matrix-metalloproteinases (MMPs). After stimulation with Poly I:C, the cells were co-incubated with increasing concentrations of the moringa seed extract and MMP levels were quantified using the ELISA assay. As a result, the moringa seed extract
displays anti-inflammatory activity by reducing MMP-1 and MMP-9 levels in vitro (Figure 5).
The moringa seed extract supports and accelerates skin recovery from irritation The objective of this study was to investigate the effect of the moringa seed extract on skin protection and recovery after irritation in vivo,
dermaroller A 100 100 100 87 B 25 20 15 14.7 10 5 0 11.6 7.7 7.2 -48% -51% 10 5 0 Untreated■ Placebo■ 2% Moringa Seed Extract■ 2% Moringa Seed Extract + SLM■
Figure 6: The moringa seed extract accelerates skin recovery after irritation. In a double-blind, placebo-controlled clinical study, volunteers’ skin was irritated using a dermaroller. The treated areas were either left untreated or treated with creams containing: 0% moringa seed extract + 0% SLM (placebo), 2% moringa seed extract, or 2% moringa seed extract + 20% SLM. A: Representative images of the forearm skin before and after dermaroller treatment illustrate the recovery process. B: The time required for complete recovery of microcirculation and TEWL after skin irritation. Mean + SEM. Statistical analysis Wilcoxon test comparing ‘treated vs. ‘untreated’. * = p < 0.05. N = 15
PERSONAL CARE May 2025
Microcirculation *
25 20 15 15.2 13.6 10.7 6.8
Skin Barrier (TEWL) *
* -30% -55% 0 Control 0.05% Moringa 0.5% Moringa Seed Extract Seed Extract
Figure 5: The moringa seed extract reduces the synthesis of matrix metalloproteinases (MMPs) in a skin cell model. HaCaT keratinocytes were seeded in 24 well plates and incubated with Poly I:C in the absence (control) and presence of the moringa seed extract (0.05% and 0.5%) for 24 hours. Unstimulated cells served as negative control. 24 hours after cell stimulation, supernatants were removed, centrifuged, and investigated for MMP-1 and MMP-9 concentrations by ELISA. Data is normalized to control (100%). Mean + SEM. Student’s T-test between ’stimulated control’ and ‘treated’. * = p < 0.05. N=3
www.personalcaremagazine.com 50 88 81 85 Before dermaroller After
while also examining the complementary benefit of Lipoid Kosmetik’s Skin Lipid Matrix SLM as an additional ingredient alongside the moringa seed extract (the moringa seed extract + SLM). Skin Lipid Matrix SLM is a biomimetic
formulation composed of essential skin lipids that create a unique three-dimensional lamellar lipid structure that replicates the natural lipid matrix of the stratum corneum. It complements the action of moringin by effectively restoring the skin’s natural protective barrier. In the study, 15 women underwent
dermaroller needling using a micro-needle device with a maximum penetration depth
Recovery 2 hours
4 hours 6 hours 150 * * * 0.5% Moringa Seed Extract
Figure 4: The moringa seed extract reduces inflammatory markers in a skin cell model. Normal human dermal fibroblasts were seeded in 24 well plates and incubated with IL-1β in the absence (control) and presence of the moringa seed extract (0.05% and 0.5%) for 24 hours. Unstimulated cells served as negative control. 24 hours after cell stimulation, supernatants were removed, centrifuged, and investigated for 8-isoprostane, PGE2
, IL-8 and IL-6
concentrations by ELISA. Shown is the cumulated data normalized to 100%. Mean + SEM. Student’s T-test between ’stimulated control’ and ‘treated’. * = p < 0.05; ** = p < 0.01; *** = p < 0.001. N=3
MMP Concentration Reduction of
MMP-1 ■ MMP-9 ■
**
*** **
** -60%
Inflammatory markers
-14%
* *
8-Isoprostane ■ PGE2 Reduction of
■ IL-8 ■ IL-6 ■
Recovery time (hours)
Recovery time (hours)
Expression Level MMP Level (%)
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96
